ARTICLE | Strategy
Eurosimilars
Why it's hard to extrapolate European biosimilars market penetration to the U.S.
July 25, 2016 7:00 AM UTC
The complex European biosimilars landscape makes it hard to extrapolate pricing, market share and switching trends to the U.S.
Across Europe, price reductions following biosimilar introduction vary widely. For example, according to IMS Health Inc., the introduction of biosimilar epoetin products led to prices decreasing 55% in Germany, 39% in France, 24% in Spain and 18% in the U.K. ...